-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AffaMed Therapeutics, a clinical-stage innovative biomedical company dedicated to meeting the global needs for the treatment of ophthalmic, neurological and psychiatric diseases, announced the appointment of Mr.
Vijay Karwal as its chief financial officer
.
Mr.
Karwal will report to the company’s CEO, Dr.
Dr.
Dayao Zhao, CEO of AffaMed, said: “I am very pleased that Vijay has joined AffaMed
at a critical moment in the development of the company .
In the field of commercial and investment banking, Vijay has a global vision.
He has not only accumulated rich experience in financial transactions and corporate strategy consulting, but also It has also achieved remarkable success
Mr.
Karwal is based in Hong Kong
Mr.
Vijay Karwal said: “Since its establishment in 2019, AffaMed has successfully built a development platform that serves patients in Greater China and the world through innovative treatment methods and solutions
.
Under the leadership of Dr.
Dayao Zhao and the strong support of investors , The company has assembled excellent teams and talents in clinical development, regulatory affairs and business development
In March 2021, AffaMed successfully completed more than US$170 million in Series B financing and announced an agreement with SIFI SpA, a leading international ophthalmology company.
) Market development, production and sales of innovative high-quality intraocular lens (IOL) products
